Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - meropenem as trihydrate - powder for solution for injection - meropenem as trihydrate 500 mg/vial - meropenem - meropenem - meronem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis. - septicemia. meronem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.

Canada - English - Health Canada

pfizer canada ulc - meropenem (meropenem trihydrate) - powder for solution - 500mg - meropenem (meropenem trihydrate) 500mg - carbapenems

Canada - English - Health Canada

sterimax inc - meropenem (meropenem trihydrate) - powder for solution - 500mg - meropenem (meropenem trihydrate) 500mg - carbapenems

Canada - English - Health Canada

sterimax inc - meropenem (meropenem trihydrate) - powder for solution - 500mg - meropenem (meropenem trihydrate) 500mg - carbapenems

Canada - English - Health Canada

eugia pharma inc. - meropenem (meropenem trihydrate) - powder for solution - 500mg - meropenem (meropenem trihydrate) 500mg

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - meropenem trihydrate 570.475mg equivalent to meropenem 500 mg - powder for injection - 500 mg - active: meropenem trihydrate 570.475mg equivalent to meropenem 500 mg excipient: nitrogen sodium carbonate - dbl meropenem for injection is indicated for treatment of the following infections, in adults and children (aged 3 months and over), when the causative organisms are known or suspected to be resistant to commonly used antibiotics: · community acquired lower respiratory tract infection · hospital acquired lower respiratory tract infection · complicated urinary tract infection · febrile neutropenia · intra-abdominal and gynaecological (polymicrobial) infections · complicated skin and skin structure infections · meningitis · septicaemia

Malta - English - Medicines Authority

accord healthcare limited - meropenem - powder for solution for infusion or injection - meropenem 1 g - antibacterials for systemic use

Malta - English - Medicines Authority

accord healthcare limited - meropenem - powder for solution for infusion or injection - meropenem 500 mg - antibacterials for systemic use

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pfizer sa-nv - meropenem trihydrate 570 mg - eq. meropenem 500 mg - powder for solution for injection/infusion - 500 mg - meropenem trihydrate 570 mg - meropenem

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - meropenem trihydrate - powder for solution for infusion or injection - meropenem trihydrate 500 mg - antibacterials for systemic use